InflaRx (IFRX) Set to Announce Earnings on Friday

InflaRx (NASDAQ:IFRX) will be announcing its earnings results before the market opens on Friday, November 8th. Analysts expect the company to announce earnings of ($0.27) per share for the quarter.

InflaRx (NASDAQ:IFRX) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.05). The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.04 million. InflaRx had a negative return on equity of 47.03% and a negative net margin of 44,046.09%. On average, analysts expect InflaRx to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

InflaRx Trading Down 1.3 %

Shares of IFRX opened at $1.55 on Friday. The company has a market capitalization of $91.26 million, a PE ratio of -1.74 and a beta of 1.57. The stock’s 50-day moving average price is $1.53 and its two-hundred day moving average price is $1.50. InflaRx has a 12 month low of $1.14 and a 12 month high of $2.10.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and set a $8.00 target price on shares of InflaRx in a research report on Wednesday, September 25th.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.